Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma
BRAF/MEK-i showed no significant benefit over upfront IPI/NIVO in matched and stratified analyses according to prognostic characteristics.
Authors
- Bart Rikhof
- Martin W. Bloem (ORCID: https://orcid.org/0000-0001-6686-5929)
- Astrid A.M. van der Veldt (ORCID: https://orcid.org/0000-0003-0446-1907)
- Geke A.P. Hospers (ORCID: https://orcid.org/0000-0002-3047-7892)
- Willeke A.M. Blokx (ORCID: https://orcid.org/0000-0002-4647-8830)
- Jan Willem B. de Groot (ORCID: https://orcid.org/0000-0002-1043-5011)
- C U Blank
- Djura Piersma (ORCID: https://orcid.org/0000-0001-5233-0296)
- Ellen Kapiteijn (ORCID: https://orcid.org/0000-0002-4814-6426)
- M J Boers-Sonderen
- A M Stevense-den Boer
- J.B.A.G. Haanen
- Michel W.J.M. Wouters (ORCID: https://orcid.org/0000-0001-6173-0662)
- Lieke H. J. Simkens
- Maureen J.B. Aarts (ORCID: https://orcid.org/0000-0002-6381-1500)
- Karijn P.M. Suijkerbuijk (ORCID: https://orcid.org/0000-0003-3604-5430)
- Franchette W.P.J. van den Berkmortel
- A.J.M. van den Eertwegh
- C D M Boreel
Institutions
- Leiden University (NL)
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- University of Groningen (NL)
- Utrecht University (NL)
- Heidelberg University (DE)
- Leiden University Medical Center (NL)
- Maastricht University Medical Centre (NL)
- Medisch Spectrum Twente (NL)
- University Hospital Heidelberg (DE)
- Medisch Centrum Leeuwarden (NL)
- Radboud University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Dutch Institute for Clinical Auditing (NL)
- Amphia Ziekenhuis (NL)
- Oncode Institute (NL)
- Máxima Medisch Centrum (NL)
- Zuyderland Medisch Centrum (NL)
- Isala (NL)
- Cancer Center Amsterdam (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1016/j.ejca.2025.116062
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Les Laboratories Pierre Fabre
- ZonMw